Percutaneous Coronary Intervention

In a new study, among low-risk patients who received primary PCI for STEMI, an early discharge pathway was shown to be both safely and successfully integrated.

A risk score based on 8 years of data showed excellent prediction of risk for contrast-induced acute kidney injury in patients undergoing PCI, researchers reported at the American Heart Association Scientific Sessions.

DAPT for 1 months or 12 months in patients with ACS undergoing PCI with a cobalt-chromium everolimus-eluting stent (Xience family, Abbott Vascular).

Among patients with left main CAD, the incidence of MACCE was similar with coronary revascularization in male and female patients, according to 10-year results of the PRECOMBAT trial.

In a pooled cohort of the two STOPDAPT-2 trials, among patients who underwent PCI, switching from dual antiplatelet therapy to clopidogrel monotherapy after 1 month reduced bleeding risk compared with 12-month DAPT.

In a new analysis from AFIRE, among patients with atrial fibrillation and stable CAD with prior coronary stenting, rivaroxaban monotherapy was superior to rivaroxaban plus an antiplatelet agent in both efficacy and safety.

In a subgroup analysis of MASTER-DAPT, regardless of whether patients had a history of MI, 1-month DAPT after PCI was noninferior to 3-month or longer DAPT for ischemic events and conferred a reduction in bleeding events.

PCI guided by quantitative flow ratio, a novel approach to estimate fractional flow reserve, was associated with lower rates of MACE at 1 year compared with PCI guided by angiography, according to results of the FAVOR III China trial.

In the FAME 3 trial, PCI guided by fractional flow reserve failed to meet noninferiority for reduction of MACCE at 1 year compared with CABG in patients with three-vessel CAD.

Among patients receiving PCI with a drug-eluting stent, use of IVUS was associated with better CV outcomes, both within and beyond 1 year after the index procedure, according to new research.